Saturday, December 28, 2024

NTRK inhibitors

 1. Larotrectinib is more specific. Entrectinib can be used for ROS1 mutations as well.

2. ORR 73%, median OS 3 yr in NTRK mutated lung adenocarcinoma ( 0.1 to 0.3%)

3.  Unique se: dizziness, wt gain, neuropathy or myopathy withdrawal pain if a dose is missed, LFT elevations. Use meclizine for vertigo and midodrine for orthostatic hypotension.

at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Primary CNS lymphoma

 Reference: Annals of Oncology  June 2024 ESMO guidelines Diagnosis  Recommendations • Contrast-enhanced cranial MRI is the recommended imag...

  • FLT 3 mutation and inhibitors in AML
    Type 1 inhibitors good against TKD and ITD FLT3 ( ITD is the one associated with shorter DOR and higher relapse rates) Type 2 ( quizartinib ...
  • Ovarian ca PARP flowchart
      Frontline is platinum based chemo with or without bev.   G ermline BRCA or HRD, negative - - Observation is ok, Niraparib cat 2A based on ...
  • Relapsed refractory DLBCL
      1. Tafasitamab - CD 19 Ab:  approved with lenalidomide for patients with R/R DLBCL ineligible for ASCT. median OS 3 yr. 2L, ineligible for...